DRUG UTILIZATION REVIEW BOARD
October 21, 2009
205 JEFFERSON STREET
JEFFERSON CITY, MO 65101

Board Members Present
John Newcomer, M.D.
Peggy Wanner-Barjenbruch, M.D.
Charlene Heyde, R.Ph
Jennifer Passanise, F.N.P
Sandra Bollinger,Pharm.D.
Randy Beckner, Pharm.D,.
Susan Abdel-Rhaman, Pharm.D.

Committee Members Absent
David Campbell, M.D.
Joseph Yasso D,O.
Joy Gronstedt, D.O.
Sharad Parikh, M.D.
Stacy Mangum, Pharm.D

MO HealthNet Staff Present
George L. Oestreich, PharmD, Dep. Division Director
Rhonda Driver, R.Ph., Pharmacy Director
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
Mary Heet, R.N.
Allison Lauf, R.N.
D.J. Johnson, Program Development Spec.
Jackie Hickman, Unit Supervisor
Angela Wilson, Medicaid Specialist
Diana Jones, Director, Clinical Services
Jayne Zemmer, Program Manager
Carol Stock, Correspondence and Infromation Specialist
Jenna Twehus, RN
Beth McQuaide, Special Assistant

Contractors Present
Annette Walther, R.N., Infocrossing
Geri Roing, R.N., Infocrossing
Tom Beetem, R.Ph., Infocrossing
Pia Mosby, ACS Healthcare
Sophie Backes, Student Inter
Jennifer Kemp-Cornelius, Pharm.D, ACS Healthcare
Mark Roaseau, Pharm.D., M.D. ACS Healthcare
Rick Pope, Pharm.D.First Health Services
Courtney Iuppa, Student Intern

Others Attending

Don Frailey, GSK	Pam Sardo, Abbott	Randy McGinley, Bayer	Grant Cale, BMS
Diane Racicot, Strativa	Gina Luebbering, Budget and Planning		Debbie King, Amgen
Rod Woods, Medimmune	Steve Levinger, P&G	Marz Hagenhoff, Scicle	Ro b Kilo, Pfizer
Richard Mesquias, Lilly	Phil King, Pfizer	Martin Early, Schering Plough	Jake Knepp,
Bob Bollinger, Forest	Barbara Belcher, Merck	Todd Houldsworth, OMJ	Lon Lowry, Novartis
Chet Steckler, Purdue			

Welcome, Introductions and Opening Remarks	John Newcomer, MD, Chairman called the meeting to order at approximately 10:00 a.m. Rhonda Driver, Director of Pharmacy introduced student interns, Sophie Backes,

	and Courtney Iuppa. Pia Mosby,a new ACS Helathcare staff member, was also welcomed.
Minutes Approval	Minutes from the August 28, 2009 conference call were approved with changes to the attendee list. (See Roll Call Vote)
Pharmacy Program Budget Update	George L. Oestreich, PharmD, Deputy Division Director discussed the overall state budget as well as the Pharmacy Program budget. He sated the Pharmacy year started very strong, with significant MAC Pricing savings being seen. Jay Bryant-Wimp provided a summary on the implementation of the Specialty MAC pricing edit. Several tough years are being projected. He noted that the Department and Division are continuing to look for overall savings opportunities. The Pharmacy program will continue with the efforts in place and look at additional opportunities to use the tools in place as well as ways to implement edits more quickly. Appreciation for the assistance the Board provides was given. Dr. Oestreich summarized the ongoing Lewin Review; preliminary information from Lewin will be released next month. Chronic Care Program successes are under review and clinical outcomes look to be very good. It is hoped fiscal outcomes will be promising as well. Discussion ensued regarding the Managed Care Carve out to Fee-for-Service which has fairly seamless. Pharmacy staff are responding to question coming in from providers needing clarification for specific medication coverage. Dr. Oestreich touched on the recent change from AWP pricing. MO HealthNet had not used AWP for several years amd the Division expects no impact from this change. He clarified the pricing formula use by the program in response to a question from the audience. No slides were presented due to the large agenda to be covered.
Review Of Prior Authorization Meeting and Public Hearing	The Drug Prior Authorization Committee met and held the public hearing, for MHD recommendations for edits under review during this quarter, on September 1, 2009. A complete Drug PA meeting packet was included with meeting handouts to the DUR Board for review and action and to all attendees. Each document and the discussion surrounding is detailed below. A copy of the draft minutes from the Drug PA Committee was included for the Board members information as well.
Old Business	
Clinical Edits **Urinary Tract Antispasmodics**	●Discussion-Ms. Driver reviewed updates to the criteria document noting the addition of a new product Toviaz® to preferred status and new product Gelnique® Gel to non preferred status. ●Decision-Following this discussion the Board voted to accept these changes to the current PDL edit. (See Roll Call Vote)

Implementation Schedule	An updated copy of the *Proposed Implementation Schedule for Edits* was included in the members' meeting packet and as a handout to all attendees. The schedule had been updated with all edits approved at the last quarter's meeting. This included the implementation following the annual review of half of the PDL done in March and April and implemented in July. The schedule may be found on the MHD Web-site at http://dss.missouri.gov/mhd/cs/pharmacy/imsched.pdf.
New Business	
New Drug Review	● Discussion- Drug monographs for products reviewed during this quarter were available at http://www.heritage-info.com/mohealthnet. A listing of products detailing MHD's recommendations for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all in attendance. Ms. Driver reviewed the recommendations and responded to questions from Board members. The manufacturer of Embeda SR provided information on titration kits for the product and expressed concern regarding splitting of blister packs. Ms. Driver spoke to these concerns and noted the 31day supply limitation would be a problem for titration kits. No calls were noted to the call center. The Board would like more data surrounding this if available. ● Decision-In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote
Synagis Edit Changes	●Discussion-Jay Bryant Wimp, RPh, Clinical Pharmacist reviewed proposed changes to the Synagis Clinical Edit. Mr. Bryant Wimp- noted recently published American Academy of Pediatrics (AAP) updated guidelines for the use of the product as well as Centers for Disease Control (CDC) and MO HealthNet hospitalization data were reviewed as the edit was being updated to create a participant centric process. Mr. Bryant-Wimp summarized a base line study complete for the 2007-2008 season. A brief comment from Rod Woods with MedImmune thanked the Committee and Division for following evidence based medicine. Concerns with risk factors were noted. Mr. Woods also requested the Division allow prior authorizations to begin now so that injections may begin the first week of November. Mr. Bryant-Wimp addressed this concern stating once the edit recommendation is approved by the Board the referrals will begin to be processed. Mr. Woods responded to a question by Board member regarding contraindication for the H1N1mist vaccine in conjunction with Synagis.

	●Decision-In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote
PDL Edits	The classes reviewed this quarter consisted of the annual review of the second half of the Preferred Drug List (PDL).
Ace Inhibitors	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was recommended for this class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Ace Inhibitor/Diuretic Combination	● Discussion-Ms. Driver reviewed the criteria document noting MHD recommendations mirrored those for the previous class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Ace Inhibitor/Calcium Channel Blocker Combinations	● Discussion- Discussion- Ms. Driver summarized this document noting no changes other than the removal of a product, Lexxel®, which is no longer manufactured. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Alpha-Glucosidase Inhibitors	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change t o the edit was recommended. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Alzheimer's Agents	● Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status and approval criteria. No change to product coverage was being recommended with the exception of a new generic product, Galantamine, to non preferred status. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Angiotensin Receptor	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products

Blockers	recommended for preferred and non-preferred status. No change was recommended for this class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Angiotensin Receptor Blocker/Diuretic Combinations	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Antidiabetic Combination Agents	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. A new product, Prandimet® was added to non preferred status. Ms. Driver reminded members that the additional criteria surrounding heart failure and TZD products will continue with this edit. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Biguanides	● Discussion- Discussion Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this class which is a generics first edit. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Bone Ossification Suppression Agents/Calcitonins	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Two new products, Skelid® and Calcitonin-Salmon Nasal, were recommended as non preferred status. All single ingredient Actonel® products (strengths) are now preferred status as well. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote with the addition of the Drug PA Committee's recommendation surrounding Actonel® products. (See Roll Call Vote)
Direct Renin Inhibitor Direct Renin	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting that all products were recommended for preferred status. Ms. Driver reminded the ARB step

Inhibitor/Combinations	edit remains in place. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Electrolye Depleters	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Changes were noted including the addition of a new product (Eliphos®) and the movement of Calcium Acetate Gel caps to non preferred status. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Herpes Antivirals	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
DMARDS	● Discussion- Discussion-Mr. Bryant Wimp reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Cimzia®, Kineret®, and Remicade®, previously preferred agents, were being recommended for movement to non preferred status. A new product, Simponi® was added to the listing in non preferred status as well. Mr. Bryant Wimp clarified that the trial and failure criteria included the trial on methotrexate. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Leukotriene Modifiers	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status Zyflo CR ® was moved to preferred status making all products in this therapeutic class preferred. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Lipotropics-Niacin Preparations	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being

	recommended for this therapeutic class. Simcor® is recommended for preferred status once a patient is compliant on extended release niacin therapy and compliant on simvastatin therapy. It was noted that the Drug Prior Authorization Committee recommended reclassifying the combo agent Advocor® to this class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote including the Drug PA recommendation to add Advicor® to this edit. (See Roll Call Vote)
Low Sedating Antihistamines	● Discussion-Ms Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was recommended. Ms. Driver noted this is an OTC first edit. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Low Sedating Antihistamines/Decongestant Combinations	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No changes were recommended. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Macrolides Adult/Pediatric	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. This is a generics first edit. No change was being recommended for this therapeutic class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Meglitinides	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Multiple Sclerosis Agents	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was

	recommended for this therapeutic class. All products in the therapeutic class were recommended for preferred status. Ms. Driver noted and oral product was about to enter the market in this therapeutic class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Narcotics: Long Acting	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. Ms. Driver noted that generic Oxycontin (non preferred) was added to the listing as it is again available. Clinical edit criteria remain in place. Ms. Driver discussed availability issues with the product Duragesic®. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Intranasal Steroids	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No changes were recommended. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Ophthalmic Antihistamines	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Ms. Driver noted the addition of Ketotifen OTC to preferred status and Ketotifen Rx to non preferred status. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Ophthalmic Mast Cell Stabilizers	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Alamast® was moved to the non preferred side of the edit. It was suggested by the Drug PA Committee that MHD review the compliance model for this therapeutic class as well as ophthalmic antihistamines given their seasonal use. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Ophthalmic Qinolones	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products

	recommended for preferred and non-preferred status including the addition of a new product Besivance® and movement to Iquix ® to non preferred status. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Ophthalmic Prostaglandin Agonists	● Discussion- Ms. Driver reviewed the proposed criteria document noting that all products in the therapeutic class are preferred. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Oral Pulmonary Hypertension Agents	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. Ms. Driver pointed out the clinical criteria still in place for approval and also discussed Missouri's data that shows the state as on outlier compared to several other states in its utilization of this therapeutic class. Student Interns are researching and MO HealthNet will have updates in December and January as the non oral versions in this therapeutic class come up for review. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Otic Quinolones	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class other than the addition of a new product Cetraxal® to non preferred status. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Quinolones-Systemic	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being recommended for this therapeutic class. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
2nd Generation Sulfonylureas	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was being

	recommended for this therapeutic class. The edit is a generics first edit. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Serotonin Receptor Agonists (Triptans)	● Discussion- Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. Changes included them movement of sumatriptan products to preferred status and Imitrex® and Relpax® to non preferred. The maximum daily dosing edit for these products remains in the edit. ● Decision-The Board recommended the edit be changed to allow transparent approval of a non preferred agent after trial and failure on one or more preferred agent(s) instead of the recommended two agents. With this change to Board approved the edit as presented. (See Roll Call Vote)
Thiazolidinediones	● Discussion- Ms. Driver reviewed the proposed criteria document. No change was being recommended for this therapeutic class. Heart failure risk clinical criteria will remain in place. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Topical Agents of Psoriasis	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change was recommended for this therapeutic class other than the addition of two new products Vectical® and Soriatane® CK to non preferred status. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Topical Retinoids	● Discussion- Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. One new product (Epiduo®) to this therapeutic class was added to non-preferred status. Differin® was moved from preferred to non preferred status. Ms. Driver pointed out clinical criteria remains in place for approval. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Ulcerative Colitis Agents	● Discussion-Ms. Driver reviewed the proposed criteria documents. Noting the

Oral and Rectal	products recommended for preferred and non-preferred status. A new product (Apriso®) to the oral therapeutic class was added to preferred status while one new product (Asacol® HD) was added to the non preferred status. Dipentum® was recommended for movement to preferred status. Ms Driver pointed out clinical criteria remains in place for approval. A new product, SFRowasa®, Enema was added to non preferred status for the rectal agents. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Vaginal Antibiotics	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting the products recommended for preferred and non-preferred status. No change to this therapeutic class was recommended. Ms Driver pointed out clinical criteria remains in place for approval. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Intranasal Antihistamines	● Discussion-Ms. Driver reviewed the proposed criteria document. Noting all products were recommended for preferred status with the addition of Pantanase® and Astepro® to preferred status. Ms. Driver pointed out clinical criteria remains in place for approval. ● Decision- In the interest of time the Board agreed to consider all recommendations as a group, reserving the right to pull any edit from the batch vote if discussion warranted. This class was added to the group vote. (See Roll Call Vote)
Preferred Drug List Announcement	A handout of therapeutic categories for review and inclusion in the PDL during the next quarter was included in the meeting packet and to all meeting attendees. This listing will be posted to the Division's Web page at http://www.dss.mo.gov.mhd. The posting will also be updated with the MHD recommendations prior to the December Drug Prior Authorization Committee meeting.
ACS HealthCare Update	Jennifer Kemp-Cornelius, PharmD. ACS Healthcare Systems summarized the current clinical edit for ADHD therapy. Slides shared provided preliminary claim and paid amounts graphs for children under six years of age. Helpdesk approval/denial statistics were also shared. Dr. Kemp-Cornelius explained at each Drug Utilization Review Board meeting she would like to pick an edit that is not routinely reviewed each year as she reviewed each of the documents.
Program Utilization Information Top 25 Report	A listing of the top 25 drugs for dates of services between January 2007 and third quarter 2008 was provided for the Boards' Information. This report was provided in two formats: ranked by number of claims and ranked by amount paid. Copies were available to all

	attendees.
Clinical Edit Summary Report	An overview of clinical edit and prior authorization transactions was provided for the month of September 2009. The report provided total transaction counts as well as information on the outcome (approval or denial) of the request. CyberAccess^{SM} log in information for the months of April 2006 through September 2009 was provided for the members review as well. Dr. Cornelius summarized these statistics including total log ins to each of the available applications. The report included active user counts as well.
Other Business/Adjourn	The next meeting of the Board is scheduled for January 20, 2010. The Drug Utilization Review Board went into executive session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See Roll Call Vote)

ROLL CALL VOTES

MEMBER	MINUTES	PA RECOMNEDATIONS	TRIPTANS	CLOSED SESSOIN	ADJOURN
John Newcomer	Yeah	Yeah	Motion	Yeah	Yeah
Susan Abdel-Rahman	Yeah	Yeah	Yeah	Yeah	Yeah
Peggy Wanner-Bargenbruch	Yeah	Second	Second	Yeah	Yeah
Randy Beckner	Yeah	* see below	*see below	Motion	Yeah
Sandra Bollinger	Motion	Yeah	Yeah	Yeah	Yeah
David Campbell	Absent	Absent	Absent	Absent	Absent
Joy Gronstedt	Absent	Absent	Absent	Absent	Absent
Charlene Heyde	Second	Yeah	Yeah	Yeah	Second
Stacy Mangum	Absent	Absent	Absent	Absent	Absent
Sharad Parikh	Absent	Absent	Absent	Absent	Absent
Jennifer Passanise	Second	Motion	Yeah	Second	Motion
Joasph Yasso	Absent	Absent	Absent	Absent	Absent

* Dr. Beckner excused himself from the votes on the following classes: Oral Anti-diabetics, Bone Ossification Suppression Agents, Urinary Tract Antispasmodics, Intra-nasal Steroids, Triptans, TZD's and Herpes Antiviral Agents. All other PDL class votes were recorded as Yeah.

Executive Session
October 21, 2009

Board Members Present
John Newcomer, M.D.
Peggy Wanner-Barjenbruch, M.D.
Charlene Heyde, R.Ph
Jennifer Passanise, F.N.P
Sandra Bollinger,Pharm.D.
.
.

Committee Members Absent
David Campbell, M.D.
Joseph Yasso D,O.
Joy Gronstedt, D.O.
Sharad Parikh, M.D.
Stacy Mangum, Pharm.D

MO HealthNet Staff Present
George L. Oestreich, PharmD, Dep. Division Director
Rhonda Driver, R.Ph., Pharmacy Director
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
Mary Heet, R.N.
Allison Lauf, R.N.
Jenna Twehus, R.N.

Contractors Present
Jennifer Kemp-Cornelius, Pharm.D, ACS Healthcare
Mark Roaseau, Pharm.D., M.D. ACS Healthcare
Rick Pope, Pharm.D.First Health Services

Minutes Review and Approval	Minutes were approved as submitted
Case reviews	Jenna Twehus, RN presented a patient profile for review and recommendation by the Board. Ms Twehus summarized the profile for a 50 year old female being treated with current pain therapy which included Oxycontin 80 mg #630/30days, Fentanyl Cit OTFC 1600 mcg/30 day and up to date MHD discussion with treating physician. The Board made recommendations which included referral for a pain pump.